---
title: "Xingqi Pharmaceutical: The first subject has been enrolled in the Phase II clinical trial of SQ-22031 eye drops for the treatment of neurotrophic keratitis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/246372690.md"
description: "Xingqi Pharmaceutical announced that its developed SQ-22031 eye drops have completed the enrollment of the first subject and officially entered the Phase II clinical trial for neurotrophic keratitis. The trial is randomized, double-blind, placebo-controlled, and parallel-controlled, and is expected not to have a significant impact on the company's recent performance"
datetime: "2025-06-27T07:48:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/246372690.md)
  - [en](https://longbridge.com/en/news/246372690.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/246372690.md)
generator: "portal-rs"
---

# Xingqi Pharmaceutical: The first subject has been enrolled in the Phase II clinical trial of SQ-22031 eye drops for the treatment of neurotrophic keratitis

According to the Zhitong Finance APP, Xingqi Pharmaceutical (300573.SZ) announced that the first subject has been enrolled today in the "Evaluation of SQ-22031 Eye Drops for the Treatment of Neurotrophic Keratitis (NK) Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Trial," officially entering Phase II clinical trials.

The completion of the first subject enrollment for SQ-22031 Eye Drops and the official entry into Phase II clinical trials will not have a significant impact on the company's recent performance

### Related Stocks

- [300573.CN](https://longbridge.com/en/quote/300573.CN.md)

## Related News & Research

- [REG - Origin Enterprises - Holding(s) in Company](https://longbridge.com/en/news/296240027.md)
- [FirstRand Bank lists ZAR 24 million structured product notes on JSE](https://longbridge.com/en/news/296356655.md)
- [Lundbeck Foundation unit Lundbeckfond Invest launches voluntary exchange offer for Lundbeck A-shares](https://longbridge.com/en/news/296304407.md)
- [Buick launches Electra L7 BEV in China, starting at $25,000 with 702-km range](https://longbridge.com/en/news/296330854.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**